BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical Highlights

Go back to BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical Highlights

Brainstorm Cell Therapeutics (BCLI) Reports Q1 Loss of $0.12/Share

May 14, 2018 8:06 AM EDT

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q1 EPS of ($0.12), versus ($0.10) reported last year.

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

... More